Entrada Therapeutics (TRDA) Earnings Date, Estimates & Call Transcripts $7.82 -0.21 (-2.56%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Entrada Therapeutics Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 6Before Market OpensEstimatedActual EPS (Feb. 27) $0.03 Beat By $0.69 Consensus EPS (Feb. 27) -$0.66 Entrada Therapeutics announced Q4 2024 earnings on February 27, 2025, reporting an EPS of $0.03, which beat analysts' consensus estimates of -$0.66 by $0.69. Quarterly revenue was reported to be $12.25 million, above analyst estimates of $11.95 million. With a trailing EPS of $1.91 and a P/E Ratio of 4.90, Entrada Therapeutics' earnings are expected to decrease next year, from $1.12 to ($3.23) per share. Earnings Press ReleaseEarnings Slide DeckPowered by TRDA Upcoming EarningsEntrada Therapeutics' next earnings date is estimated for Tuesday, May 6, 2025, based off prior year's reporting schedules. Get Entrada Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entrada Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataTRDA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TRDA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Entrada Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.92-$0.72-$0.82Q2 20252-$1.00-$0.75-$0.88Q3 20252-$1.06-$0.79-$0.93Q4 20252-$1.12-$0.69-$0.91FY 20258-$4.10-$2.95-$3.53Q1 20261-$0.73-$0.73-$0.73Q2 20261-$0.76-$0.76-$0.76Q3 20261-$0.81-$0.81-$0.81Q4 20262-$0.86-$0.86-$0.86FY 20265($3.16)($3.16)($3.16) Remove Ads Entrada Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/6/2025(Estimated)-------2/27/2025Q4 2024-$0.66$0.03+$0.69$0.03$11.95M$12.25M8/13/2024-$0.65$1.55+$0.90$1.55$55.00M$94.69M5/7/2024Q1 2024-$0.38$0.68+$1.06$0.68$25.00M$59.12M3/13/2024Q4 2023-$0.07-$0.29 -$0.22-$0.29$27.82M$41.85M11/7/2023Q3 2023-$0.55$1.02+$1.57$1.02$16.31M$43.74M8/8/2023Q2 2023-$0.43-$0.78 -$0.35-$0.78$19.56M$18.17M5/10/2023Q1 2023-$0.77-$0.21+$0.56-$0.21-$25.26M Entrada Therapeutics Earnings - Frequently Asked Questions When is Entrada Therapeutics's earnings date? Entrada Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based off last year's report dates. Learn more on TRDA's earnings history. Did Entrada Therapeutics beat their earnings estimates last quarter? In the previous quarter, Entrada Therapeutics (NASDAQ:TRDA) reported $0.03 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.66) by $0.69. Learn more on analysts' earnings estimate vs. TRDA's actual earnings. How much revenue does Entrada Therapeutics generate each year? Entrada Therapeutics (NASDAQ:TRDA) has a recorded annual revenue of $210.78 million. How much profit does Entrada Therapeutics generate each year? Entrada Therapeutics (NASDAQ:TRDA) has a recorded net income of -$6.68 million. TRDA has generated $1.91 earnings per share over the last four quarters. What is Entrada Therapeutics's price-to-earnings ratio? Entrada Therapeutics (NASDAQ:TRDA) has a trailing price-to-earnings ratio of 5.04 and a forward price-to-earnings ratio of 7.16. What is Entrada Therapeutics's EPS forecast for next year? Entrada Therapeutics's earnings are expected to decrease from $1.12 per share to ($3.23) per share in the next year. More Earnings Resources from MarketBeat Related Companies Indivior Earnings Date Dyne Therapeutics Earnings Date Wave Life Sciences Earnings Date ARS Pharmaceuticals Earnings Date Calliditas Therapeutics AB (publ) Earnings Date Ardelyx Earnings Date Ocular Therapeutix Earnings Date Structure Therapeutics Earnings Date Aurinia Pharmaceuticals Earnings Date Adaptive Biotechnologies Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Remove Ads This page (NASDAQ:TRDA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRDA Stock Free TRDA Stock Alerts